▎ Tirzepatid Risach
Wetin na di risach bakgrɔn fɔ Tirzepatid?
di divεlכpmεnt fכ Tirzepatid, we na sεntetik polypεptida dכg, kכmכt frכm we dεn no di limitεshכn dεm fכ GLP-1 rεsεptכr agonist dεm fכ trit tayp 2 dayabεtis εn fכ fat. pan ɔl we di GLP-1 rεsεptכr agonist dεm de εksεl in bכdi glukכs kכntrכl εn weit lכs, sayɛnsman dεm fכnshכn se dεn wik aktibכshכn fכ GIP rεsεptכr dεm de limited tεrapi ifekt dεm. so, risach tim dεm bin aim fכ divεlכp nכvel drog dεm we ebul fכ aktibכt כl tu di GIPR εn GLP-1R fכ mכr kכmprεhεnsiv glycemic kכntrכl εn wet mεnejmεnt [1]..
Dɛn bin du bɔku prɛklinik ɛn klinik trayal dɛn we dɛn bin de du di divɛlɔpmɛnt.
Prεklinik animal stεdi dεm evaluate fכmakodaynamik prכpati dεm, we kכnfכm in pכtεnshal in glycemic kכntrכl εn weit lכs. Faz I klinik trayal dεm bin fכs ases sef, tכlerabiliti, εn fכmakokinetiks, we sho gud sef
ɛn we pɔsin kin ebul fɔ bia wit am. Faz II trayal dεm bin fכs εksplכr di efεktiv εn sef pan difrεn doz dεm insay tayp 2 dayabεtis pasεnshכn dεm, fכs dεtermine di ifektiv doz rεnj dεm. Pivotal Phase III trials lεk di SURPASS siriכs, we involv big kכhכt dεm fכ tayp 2 dayabεtis pasεnshכn dεm, sho se Tirzepatid sכmtεm pas di GLP-1 rεsεptכr agonist dεm we de naw fכ lכs blכd glukכs εn wet, we gi robust pruf fכ makεt aplikεshכn [1]..
i kכmכp fכ 39 amino asid dεm wit strכkchכral modifyushכn fכ εnhans stεbiliti εn efikכs, in yכnik strכkchכ de intagret di akshכn dεm fכ GIP εn GLP-1 insay wan mכlikul, we de aktibכt כmon rεsεpכta dεm we involv insay glycemic kכntrכl tru tu mεkanism dεm.
na wan say, i de wok pan di pankrias fכ mek insulin sekreshכn εn fכ mek di glukכn kכmכt fכ ridyus di glukכs na di bכdi; na di כda say, i de wok pan di sεntri nεv sεstem fכ delay di gεstrik εmpti, inkrεs fכ sati, εn rεdכks fכ it εn it fכ mεnejmεnt di wet. Dis tu mεkanism de gi Tirzepatid yunik advantej fכ trit tayp 2 dayabεtis εn fat, we de gi di sik pipul dεm mכr kכmprεhεnsiv tεrapi opshכn dεm [1]..
Wetin na di we aw Tirzepatid de wok?
Tirzepatid de lכs di glukכs na di bכdi tru mכltipכl mεkanism dεm:
aktibכshכn fכ GLP-1 rεsεpכta dεm: i de biεnd to GLP-1 rεsεpכta dεm pan pankrεas β sεl dεm, i de mεkכl nεchכral GLP-1 fכ protεkt insulin sεntesis, sekreshכn, εn glukכs sεns we i de ridyus glukכn sekreshכn fכ εnhans satiety εn sכpres apεtit. pan tayp 2 dayabεtis pasεnshכn dεm, we dεn aktibכt GLP-1 rεsεpכta dεm de inkrεs insulin sekreshכn fכ impruv glycemic kכntrכl, we fכ inhibit glukagon rilis de ridyus bכdi glukכs sכs dεm mכr, we de εp glycemic rεguleshכn [2]..
aktibכshכn fכ GIP rεsεpכta dεm: we i de akt pan GIP rεsεpכta dεm, aktibכshכn de εnhans insulin sεnsitiviti εn sekreshכn. di GIP risεptor dεm de mεnli insay tisu dεm lεk pankrεas β sεl dεm, εn aktibכshכn tru intasεlulyar signal path dεm de inkrεs insulin sekreshכn εn impruv sεl rεspכns to insulin fכ mכr ifektiv bכdi glukכs rεdukshכn [2] . dis dual risεptor agonism de mek Tirzepatid mכr ifektiv fכ promuot insulin sekreshכn εn inhibit glukagon rilis pas singl GLP-1 rεsεpכta agonist dεm [2]. .
Dilayed Gastric Emptying and Increased Satiety: I de delay gastric emptying, i de mek di it de rεtεn di bεlε fכ lכng fכ slo di nyutriεnt absכpshכn εn avכyd postprandial bכdi glukכs spik. Na da tɛm de, we yu de akt pan di sɛntral nɛvɔ sistɛm fɔ mek yu satisfay, i de ridyus di apɛtit ɛn it we yu de it, mɔ i fayn fɔ fat bɔku tɛm we kin gɛt fɔ du wit tayp 2 dayabitis, we de ɛp fɔ mek di insulin rɛsistɛns ɛn di ɔvala mɛtabolik stetɔs bɛtɛ [3]..
Impruv Insulin Sεnsitiviti εn Lipid Mεtabolism: fכ εlevεt di adiponectin lεvεl dεm—wan fεt sεl fכktכ we riliyt to insulin sεnsitiviti—de εp fכ impruv insulin sεnsitiviti, we de mek sεl dεm ebul fכ tek εn yuz glukכs mכr efyushכn fכ ridyus glukכs na di bכdi [2] (Anonymous, 2023). i de impruv di lipid profayl dεm bak, wit pכtεnshal prכtektiv ifekt dεm pan di kכdivaskyul hεlth, dεn sho se i de impruv bכdi prεshכn εn rεdכks LDL kכlestכl εn triglisεrayd [3]..
Wetin na di stɔdi dɛn we gɛt fɔ du wit dis?
Tirzepatid de sho se i gɛt impɔtant ɛfifikɛshɔn pan di wet mɛnejɛmɛnt fɔ di wan dɛn we fat ɛn we gɛt tayp 2 dayabitis. Insay di SURMOUNT-2 stεdi, wan Faz 3, dכbl-blaynd, randomizεd, plasεbo-kכntrol trial we dεn kכnεkt na sεvin kכntri, big pipul dεm we ol ≥18 ia wit BMI ≥27 kg/m² ɛn HbA1c 7–10% bin randomiz fɔ gɛt wik sabkyutan tirzepatide (10 mg ɔ 15 mg) ɔ plasɛbo fɔ 72 wik. Bay wik 72, di weit lɔs pasɛnt na bin −12.8% ɛn −14.7% insay di tirzepatide 10 mg ɛn 15 mg grup dɛn versus −3.2% insay di plasɛbo grup, wit ɛstimat tritmɛnt difrɛns we na −9.6 ɛn −11.6 pasɛnt poɛnt kɔmpia to plasɛbo (p < 0.0001). Apat frɔm dat, mɔ tirzepatide-trit pasɛnt dɛn ajɔst ≥5% weit lɔs (79–83% vs. 32%) (Garvey WT, 2023). Wit beslayn min wet 100.7 kg, BMI 36.1 kg/m², ɛn HbA1c 8.02%, 72 wik tritmɛnt wit tirzepatide nɔ jɔs ridyus di wet bɔku bɔku wan bɔt i impɔtant bak fɔ mek di glycemic kɔntrol [4]. .
Fɔ impɔtant nyuropathy we gɛt fɔ du wit dayabitis, risach dɔn sho se GLP1-RA dɛn kin ridyus di dimɛnsi risk pan tayp 2 dayabitis pasɛnt dɛn bay we dɛn kin ɛp fɔ mɛmba, lan, ɛn win di prɔblɛm we dɛn kin gɛt pan di tin dɛn we dɛn kin no. As dual GIP-RA/GLP-1RA, Tirzepatid bin stכdi in nyuroblastoma sel layn (SHSY5Y) fכ in ifekt pan nyuronal growth (CREB εn BDNF), apoptosis (BAX/Bcl2 rεshכ), difrεns (pAkt, MAP2, GAP43, εn AGBL4), εn insulin rεsistεns (GLUT1, GLUT4, GLUT3, εn SORBS1) mak dɛn. i fכnshכn fכ εksyεrt nyuroprotεktiv ifekt dεm bay we i de aktibכt di pAkt/CREB/BDNF path εn dכwnstrim signal kaskad, we de kכntrכl haypa glycemia- εn insulin rεsistεns-rεlatεd ifekt dεm na di nyuronal lεvεl. So, Tirzepatid kin impruv di nyurodijεnεreshכn we de kכmכt na di haypa glycemia εn i kin כvakom di nyuronal insulin rεsistεns, we de gi nyu tin dεm fכ mεnεj nyuropathy we rilayt to dayabεtis [5]..
Insay tayp 2 dayabitis tritmɛnt advansmɛnt, Tirzepatid, wan nyu haypoglycemic drɔg, bi di fɔs aprɔv dual GIP/GLP-1R agonist fɔ dayabitis na di US Bɔku big klinik trial dɛn kɔnfɔm in signifyant glycemic-lɔring ɛn weit-lɔs ifɛkt, wit pɔtɛnɛshɛl fɔ kadiovaskular protɛkshɔn. di kכnsεpt fכ sεntetik pεpti dεm dεn opin bכku posisibul dεm we dεn nכ εksplכr fכ Tirzepatid. Trial ɛn pruf dɛm we de go bifo sho se na prɔmis drɔg fɔ non-alcoholic fatty liver disease (NAFLD), rεnal protεkshɔn, ɛn nyuroprotεkshɔn [6]..
Fɔ tɔk bɔt di lɔng tɛm ifɛkt pan di at ɛn di blɔd wɛlbɔdi, Tirzepatid kin ridyus di risk fɔ di at ɛn di blɔd sik (CVD) bay we i de mek pɔsin lɔs in wet. Wan stכdi we dεn εgzamin di impak we tirzepatide gεt pan di fat εn CVD ivent dεm pan US big pipul dεm fכnshכn se pan dεn wan dεm we fit fכ tirzepatide tritmεnt, dεn εstimat 15 mg tεrapi fכ achy ≥15% εn ≥20% weit lכs insay 70.6% εn 56.7% pan big pipul dεm, rispεktivli, we translet to 58.8% rεdukshכn pan fat prεvalεns. pan pipul dεm we nכ gεt CVD, di εstimat 10 ia CVD risk dכn dכn frכm 10.1% 'pri-tritmεnt' to 7.7% 'post-tritmεnt,' we riprizent absכlut risk rεdukshכn fכ 2.4% εn rilitiv risk rεdukshכn fכ 23.6%, we pכtεnshal fכ prεvεnt 2 miliכn CVD ivin dεm [7].
Dɔn
fכ sכmari, Tirzepatid na nכvel dual agonist fכ GIP εn GLP-1 rεsεpכta dεm, we de ol sכm imכpכtants fכ trit tayp 2 dayabεtis εn fכ fat. i de mכr ifektiv fכ mek insulin sekreshכn, inhεbit glukagon rilis, εn prεsisli rεgεl di bכdi glukכs, i de ridyus di kכmplikεshכn risk dεm we i de impruv pankrεas β-sεl fכnshכn εn delay dayabεtis prכgreshכn, wit kכdiprotεktiv ifekt dεm. Insay tritmɛnt fɔ fat, i de ridyus di it we pɔsin de it fayn fayn wan, i de stɔp fɔ it, i de mek pɔsin satisfay, i de ɛp fɔ lɛ pɔsin nɔ gɛt bɔku bɔku bɔdi, ɛn i de mek di prɔblɛm dɛn we kin apin we pɔsin fat pasmak, ɛn i kin mek di insulin nɔ de wok fayn ɛn di lipid mɛtabolism bɛtɛ. Apat frɔm dat, i de sho se i kin ebul fɔ trit mɛtabolik disɔda lɛk nɔ-alkoholik stiatohepatitis, slip apnea sindrom, ɛn at fayl, we de gi kɔmprɛhɛnsif tritmɛnt bay we i de ɛp fɔ mek bɔku mɛtabolik paramita dɛn bɛtɛ. Di injɛkshɔn schedule we i gɛt wan tɛm insay di wik de mek i izi fɔ du ɛn di pɔsin we sik de fala di lɔ. We Tirzepatid de kɔntrol di glukɔs ɛn wet na di blɔd fayn fayn wan, ridyus di prɔblɛm dɛn we kin apin to pɔsin, ɛn i kin mek dɛn bɔdi, di tin dɛn we dɛn kin du ɛvride, ɛn di kwaliti fɔ layf bɛtɛ, i kin mek di sikman dɛn gɛt kɔnfidɛns pan di we aw dɛn de mɛn di sik, i kin mek dɛn nɔ gɛt bɔku prɔblɛm dɛn we dɛn kin gɛt na dɛn maynd, ɛn i kin mek dɛn ebul fɔ adap to ɔda pipul dɛn.
Bɔt di pɔsin we rayt di buk
Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.
Sayɛns Jɔnal Author
Dɔktɔ Wiliam T. Gavi na wan big masta sabi bukman ɛn risachman we gɛt fɔ du wit bɔku bɔku big big institiushɔn dɛn, lɛk di Yunivasiti ɔf Alabama na Bɛmingham, Aston Yunivasiti, ɛn di Bɛmingham Veterans Afɛj Mɛdikal Sɛnta. In akademik bakgrɔn ɛn in wok ɛkspiriɛns span bɔku difrɛn disiplin dɛn insay di mɛdikal ɛn sayɛns fild dɛn. Dɔktɔ Garvey dɔn mek bɔku kɔntribyushɔn to di fild dɛm fɔ ɛndokrinɔlɔji ɛn mɛtabolism, nyutrishɔn ɛn itɛttiks, bayɔkemistri ɛn mɔlikul bayoloji, ɛn bak jenɛral ɛn intanɛnt mɛrɛsin, wit patikyula fɔs pan di kadiovaskular sistɛm ɛn kadiɔlɔji. Bɔku pipul dɛn dɔn no ɛn ɔnɔ in wok, mɔ we dɛn kɔl am Highly Cited Researcher in di Cross-Field kategori fɔ ɔl tu di 2023 ɛn 2024, we sho di big impak ɛn inflɛns we in risach gɛt pan di brayt sayɛns kɔmyuniti.
Dכkta Garvey in risach intres εn εkspεriεns de εksεnd to difrεn aspek dεm fכ mεtabolik sik dεm εn dεn mεnejmεnt. I dɔn de wok tranga wan fɔ stɔdi bɔt dayabitis, fɔ fat, ɛn di prɔblɛm dɛn we gɛt fɔ du wit dɛn, ɛn i dɔn aim fɔ fɛn nyu tritmɛnt strateji ɛn fɔ mek di pɔsin gɛt bɛtɛ tin fɔ du. In wok inkɔmpas besik sayɛns risach, klinik trial, ɛn transleshɔnal stɔdi, we de briŋ di gap bitwin di tin dɛn we dɛn dɔn fɛn na lɛbɔretri ɛn di rial wɔl mɛdikal aplikeshɔn dɛn. Tru in bɔku risach, Dɔkta Garvey dɔn kɔntribyut fɔ ɔndastand mɔ bɔt di ɔndalayn mɛkanism dɛm fɔ mɛtabolik dizayd ɛn i dɔn ɛp fɔ shep klinik gaydlayn ɛn tritmɛnt protɔkɔl dɛm na di fild fɔ ɛndokrinɔlɔji ɛn mɛtabolism. Dɛn rayt Dɔktɔ Wiliam T. Gavi insay di rɛfrɛns fɔ saytayshɔn [4].
